US87184Q2066 - Common Stock
On Friday, there are stocks with unusual volume. Let's take a look.
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.
Top movers analysis in the middle of the day on 2024-11-13: top gainers and losers in today's session.
Gap analysis on 2024-11-13: gap up and gap down stocks in today's session.
Get insights into the top gainers and losers of Wednesday's pre-market session.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals,...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals,...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
Syros Pharmaceuticals stock is down on Tuesday as SYRS investors react to the company discontinuing enrollment for a clinical trial.
It's time to dive into the biggest pre-market stock movers for Tuesday as we check out all of the hottest news moving shares this morning.
SYRS stock results show that Syros Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.